Publications
- Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy2018 | Second Faculty of Medicine
- Chapter Three - Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents2017 | Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Trial watch: Immune checkpoint blockers for cancer therapy2017 | Second Faculty of Medicine
- Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer2015 | Second Faculty of Medicine
- Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs2014 | Second Faculty of Medicine, Central Library of Charles University
- Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials2011 | Second Faculty of Medicine
- Type I interferon and cancer2024 | Second Faculty of Medicine
- Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma2023 | First Faculty of Medicine, Second Faculty of Medicine
- Trial watch: chemotherapy-induced immunogenic cell death in oncology2023 | Second Faculty of Medicine
Loading network view...